Ebru TEKBAŞ, Zuhal ARUTÜRK, Habib ÇİL, Yahya İSLAMOĞLU

Famotidine-induced acquired long QT syndrome: a case report

Bir çok ilacın uzun QT sendromuna yol açtığı bilinmektedir. Famotidinin sık kullanımına rağmen bu ilacın neden olduğu uzun QT sendromu nadiren bildirilmiştir. Biz famotidinle ilişkili kazanılmış uzun QT sendromlu bir olgu sunduk.

Anahtar Kelimeler:

Elektrokardiyografi, Orta yaşlı, Erkek, Famotidin, QT aralığı

Famotidinin uyardığı uzun QT sendromu: olgu sunumu

It is known that a number of drugs caused acquired long QT syndrome. Although the often use of famotidine, acquired long QT syndrome associated with this drug has rarely been reported. We presented a case of famotidine associated with acquired long QT syndrome.

Keywords:

Electrocardiography, Middle Aged, Male, Famotidine, QT interval,

PDF

___

1. Cahoon WD Jr. Acquired QT prolongation. Prog Cardiovasc Nurs 2009;24(1):30-3
2. Hulisz DT, Welko JR, Heiselman DE. Sinus arrest associated with continuous-infusion cimetidine. Pharmacotherapy 1993;13(1):64-7
3. Endo T, Katoh T, Kiuchi K, Katsuta Y, Shimizu S, Takano T
Famotidine and acquired long QT syndrome. Am J Med 2000;108(5):438–9
4. Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM
Famotidine and long QT syndrome. Am J Cardiol 2004;93(10):1325-7
5. Gunasekaran TS, DuBrow I. Cisapride-induced long QT interval: what is the role of ranitidine? J Pediatr 1997;130(4):679-80
6. Yang J, Russell DA, Bourdeau JE. Case report: ranitidineinduced bradycardia in a patient with dextrocardia. Am J Med Sci 1996;312(3):133-5
7. Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Shimizu- Sasamata M, Sato S, et al. Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol 2003;466(1-2):137-46
8. Kenigsberg DN, Khanal S, Kowalski M, Krishnan SC
Prolongation of the QTc interval is seen uniformly during early transmural ischemia. J Am Coll Cardiol 2007;49(12):1299-305
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45